88
Participants
Start Date
February 20, 2018
Primary Completion Date
September 15, 2020
Study Completion Date
September 16, 2020
Udenafil
Open-label extension with Udenafil 87.5 mg BID treatment for 52 weeks.
Children's Hospital of Philadelphia, Philadelphia
Nemours Cardiac Center/Alfred I. duPont Hospital for Children, Wilmington
Children's National Medical Center, Washington D.C.
Medical University of South Carolina, Charleston
Children's Healthcare of Atlanta, Atlanta
Vanderbilt University Medical Center, Nashville
Cincinnati Children's Hospital Medical Center, Cincinnati
Children's Hospital of Wisconsin, Milwaukee
Children's Mercy Hospital, Kansas City
Children's Mercy Hospital Kansas City, Kansas City
University of Nebraska Children's Hospital and Medical Center, Omaha
Texas Children's Hospital, Houston
Children's Hospital Colorado, Aurora
Primary Children's Medical Hospital/Dept. of Pediatric Cardiology, Salt Lake City
Boston Children's Hospital, Boston
University of Michigan Congenital Heart Center, Ann Arbor
The Hospital for Sick Children, Toronto
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Mezzion Pharma Co. Ltd
INDUSTRY